EquityBulls

Latest News

Tamilnadu Petroproducts Ltd receives TNPCB nod for expanded capacity of Linear Alkyl Benzene plant
S&P Upgrades IIFL Finance's Outlook to 'Positive' On Recovering Market Share in Gold Loans, 'B+/B' Ratings Affirmed
Trishakti Industries Ltd secures order from Afcons Infrastructure Ltd
Persistent and DigitalOcean announce strategic partnership to advance accessible, scalable and secure AI
ITCONS E-Solutions Ltd bags new contract

Keywords Selected: INE935A01035

Stock Report

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma
Glenmark Pharmaceuticals Inc., USA to launch Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial
Glenmark Pharmaceuticals Ltd update on USFDA PAI at Chhatrapati Sambhajinagar Facility
Glenmark Pharmaceuticals Receives Establishment Inspection Report (EIR) from U.S. FDA for its Monroe facility
Glenmark Pharmaceuticals announces Launch of Nebzmart® GFB Smartules® and Glenmark Airz® FB Smartules®, World's First Nebulized Triple Therapy for COPD
Cosmo and Glenmark announce Market Authorization of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 15 countries in Europe
Glenmark Pharmaceuticals Announces Q2FY26 Results
Glenmark Secures China Approval For RYALTRIS®, Reinforcing Respiratory Innovation Leadership
Glenmark Pharmaceuticals Inc., USA to launch 8.4% Sodium Bicarbonate Injection USP, 50 mEq/50 mL (1 mEq/mL) Single-Dose Vial
Glenmark Pharmaceuticals Inc., USA to launch Ropivacaine Hydrochloride Injection USP
Glenmark Strengthens Oncology Portfolio with Hengrui's HER2 Targeting ADC For Multiple Regions
Glenmark Pharma arm receives upfront payment of $700 Mn from AbbVie
Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials
Glenmark Pharmaceuticals Inc., USA to launch Micafungin for Injection USP, 50 mg/vial and 100 mg/vial
Ichnos Glenmark Innovation announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
Ichnos Glenmark Innovation and AbbVie announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
Glenmark Pharmaceuticals Launches TEVIMBRA® in India
U.S. FDA inspection at Glenmark Pharma's Facility at Monroe, North Carolina, USA
Glenmark Pharmaceuticals to Launch DCGI-approved BRUKINSA® in India to Advance Treatment of Hematological Malignancies
Ichnos Glenmark Innovation receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
Glenmark Pharmaceuticals Inc., USA to launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
Glenmark Pharmaceuticals Inc., USA launches Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-Dose Vial)
Glenmark receives ANDA approval for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%
Glenmark Pharma expands Cardiometabolic Portfolio with the Launch of Empagliflozin and its Fixed-Drug Combinations in India